One stop for all your health tips

Brunello Cucinelli Full-Year Revenues Rise 11.5% on Strong US and Asia Demand
Brunello Cucinelli Full-Year Revenues Rise 11.5% on Strong US and Asia Demand
Who Sets the Trend for Suits, Layering and Long Capes?
Who Sets the Trend for Suits, Layering and Long Capes?
Ssense Avoids Bankruptcy Sale as Founders Retain Control
Ssense Avoids Bankruptcy Sale as Founders Retain Control
MENS HEALTH FITS. ALL RIGHTS RESERVED.

5

Apr , 2024
Therapeutic potential of CD20 x CD3 bispecific antibodies
Tag: Bispecific antibody

Therapeutic potential of CD20 x CD3 bispecific antibodies

On Monday, March 25th, 2024, the U.S. FDA declined approval for Regeneron’s Odronextamab for two forms of lymphoma due to concerns over the progress of ongoing confirmatory trials. Cancer immunotherapy with CD3 bispecific antibodies (BsAbs) is a fast-developing field. As of March 2024, the FDA has approved three CD20 × CD3 BsAbs: mosunetuzumab (Lunsumio) for […]

29

Oct , 2023
MHRA grants conditional marketing authorization for AbbVie’s Tepkinly to treat aggressive blood cancer
Tag: Bispecific antibody

MHRA grants conditional marketing authorization for AbbVie’s Tepkinly to treat aggressive blood cancer

AbbVie today announced that the UK Medicines and Healthcare products Regulatory Agency has granted conditional Marketing Authorisation for Tepkinly® (epcoritamab) as a monotherapy for the treatment of adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), after two or more systemic therapies. The conditional Marketing Authorization for Great Britain is based on the […]